Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Pharmacy | Allergy | Journal

Back to Journal Articles

rhC1INH Cuts Attack Frequency in Hereditary Angioedema

Last Updated: November 08, 2012.

 

Weekly administration for eight weeks well tolerated; linked to reduction in attack frequency

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with hereditary angioedema, weekly administration of recombinant C1INH is well tolerated and is associated with a reduction in attack frequency, according to a study published online Nov. 5 in Allergy.

THURSDAY, Nov. 8 (HealthDay News) -- For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency, according to a study published online Nov. 5 in Allergy.

Avner Reshef, M.D., from the Chaim Sheba Medical Center in Tel Hashomer, Israel, and colleagues examined the safety and prophylactic effect of weekly administration of rhC1INH (50 U/kg body weight) in a study involving 25 patients with a history of HAE attacks occurring at least every two weeks. Following a two-week run-in period, patients received rhC1INH administration every week for eight weeks, and were followed for an additional six weeks.

The researchers found that, over the past two years, participants reported attacks at a rate of 0.9/week. During the treatment period, the mean attack rate was 0.4/week. In 13 patients, 30 treatment-emergent mild-to-moderate adverse events were reported. Twenty-five days after the last study drug administration, one patient died from a laryngeal attack. Dry mouth, dizziness, and anxiety were reported as the only possible drug-related adverse events in one patient and hypotension was reported in another. No allergic adverse events were reported.

"In summary, weekly administration of 50 U/kg rhC1INH appeared to reduce the frequency of HAE attacks and was generally safe and well tolerated," the authors write. "These encouraging findings warrant further investigation of the clinical value of prophylaxis with rhC1INH."

Several authors disclosed financial ties to the biotechnology industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Mammogram Interpretation Agreement Varies by Finding Next: Conical Fiber Tips Best for Cutting Efficacy in Oral Surgery

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.